8 results
(1) Investigate diagnostic performance (sensitivity) of HD bronchoscopy, with or without surface enhancement or tone enhancement in comparison to standard WLB for detecting abnormalities of the tracheobronchial tree. Furthermore we aim to…
Primary objective:Determing the positive predictive value and diagnostic yield of HD+ i-scan bronchoscopy for vascular pattern detection .Secondary objectives:1. To investigate the correlation of vascular abnormalities with histology2. To…
Primary:• Compare progression-free survival (PFS) as assessed by the Independent Review Committee (IRC) per Response Evaluation Criteriain Solid Tumors (RECIST) Version (v) 1.1 in ociperlimab plus tislelizumab (Arm A) versus Durvalumab (Arm C) among…
Safety Run-in (SRI) part:To confirm the recommended phase 2 dose (RP2D) of NIS793 or any other investigational drug(s), in combination with SOC anti-cancer therapy. In protocol amendment 1, an arm with tislelizumab has been added. In this arm, the…
Primary objectives:Dose Escalation• To assess the safety and tolerability of JDQ443 single agent and JDQ443 in combination with TNO155, JDQ443 in combination with tislelizumab, and JDQ443 in combination with TNO155 and tislelizumab, and to identify…
To investigate whether daily electrical stimulation of gluteal and hamstring muscles combined with usual care is more effective than only usual in individuals with chronic SCI who often have PU*s and/or are at high of recurring PU*s regarding: 1)…
Primary:• To compare progression free survival (PFS) between Arm A (ociperlimab in combination with tislelizumab) and Arm B (pembrolizumab followed by placebo) in the Intent to Treat (ITT) Analysis Set as assessed by investigators according to…
Primary objective:- To compare the efficacy of zanidatamab in combination with chemotherapy or in combination with chemotherapy and tislelizumab to the efficacy of trastuzumab in combination with chemotherapy in subjects with unresectable locally…